Acrux Limited · ASX:ACR
Acrux — Investor Presentation (March 2007)
14 slides from Acrux's investor presentation, Mar 21, 2007
Slide 1: Material progress with Acrux
i Ae 7. We say : We eee aa ye Le. CC 2 yy ye TN see a ne : ; Lo 5 a i eee STAR i ‘ eo a it tL Ha ee MATERIAL PROGRESS WITH Mi Acc ns Le 2 NNN ae LO: ae oF oo 7 Lo i ii cna Lee Ley) cn TT SSA MMII 2 MTN nan a Sinn EFT : : y tie ae ae oy i
Slide 2: Forward-looking statements disclaimer
This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be materially different from the statements in this pres
Slide 3: Acrux share price July 2005 - March 2007; material progress
Nt Cents per Share Acrux (ACR) share price July 2005 - March 2007 140 430 120 410 100 90 Bo 40 si “0 Jul-OS Seap-05 Nov-05 Jan-06, Apr-06 Jun-06- Aug-06 Now 06 Jan-O7 Material progress..... \ Two licensing deals with Organon \ EvaMist™ US marketing application submitted \ Testosterone for men Phase
Slide 4: et, Lo
yy es et, Lo CUES SU Dr Adam Watkinson Tim Saunders Dr Richard T reagus TT ain 7 oo - 7 : Vee a —New compounds Testosterone MD-Lotion® —Partner Performance —Technology improvements —Fentanyl UDTS™ —New Licence Agreements — Synergistic technologies —Contraceptive sprays — Collaborative Agreements 2 o
Slide 5: Target market
Target market ‘ $n) Formulation Phase1PK Phase 2PK Phase 2 Phase 3 Registration Current Partner Therapeutic Area efficacy Menopausal symptom: : FvaMist!™ (Est Decreased libide in women Contraception Chronic pain entanyl UDTS™ Male testosterone deficiency ‘Testosterone MD-Lotion| g Yj Companion anima
Slide 6: Organon licence deals
¢ Healthcare business of Akzo Nobel; a leader in women’s health - number 3 in US$6.7 billion global contraception market ¢ Organon funds all clinical, regulatory and commercialisation in two worldwide licence deals: Organon selects contraceptive compounds for development as spray Acrux earns US$12-1
Slide 7: EvaMist US marketing application submitted and accepted by FDA
So * US marketing application submitted by VIVUS and accepted by FDA * US$3m due from VIVUS on approval of application, then royalties * US estrogen-alone therapy market US$1.3 billion — Estrogen is most effective treatment for menopause symptoms — Transdermal estradiol has safety advantages over es
Slide 8: Testosterone for women: US development stalled, Europe options
Ne * US development stalled - VIVUS still negotiating with FDA on Phase 3 design * Remains a huge market opportunity — certainty on regulatory requirements likely to trigger commercial interest « Acrux enforcing VIVUS performance obligations * Procter & Gamble launching testosterone patch in Europe
Slide 9: Testosterone MD-Lotion for men
ou Global market US$0.6 billion, dominated by Androgel® US market research confirms strong patient preference for Acrux’s convenient and discreet lotion over current therapies Patent pending protects unique application to the armpit until 2026 Phase 2 trial in progress in USA under IND; results due
Slide 10: Fentanyl UDTS
UDTS™ unit dose presentation less compelling than MDTS® — control of dose, ease of use, flexibility Formulation efficiency significantly improved — enables simple delivery using MDTS® to match entire Durogesic® patch range IND application submission due Q2 2007 Phase | pk trial confirming MDTS® dosi
Slide 11: Cash reserves and revenue sources
One * Cash reserves $19m - cash outflow FY 2005/06 $8.3m « Priority to grow revenue from new & existing licences * Research and commercialisation are scalable at fixed cost — development costs are variable and controllable « Target is revenue growth to drive profitability in 2008 « Existing licensin
Slide 12: Share ownership
0 SHARE OWNERSHIP (TOTAL 142.6m) institutions 40% other / retail 48% directors & | 6.4m (4.5%) employee options outstanding managers at prices 69¢ to $1.20 12% Controlled improvement in register quality: — Nov 2006 to Feb 2007; former CEO options expiry — 4m options expired, 8m shares placed/sold —O
Slide 13: 2006/07 milestones and achievements
HS Licensing - secure significant new deal (2 deals achieved) EvaMist™ - VIVUS files marketing application with FDA (achieved) Testosterone MDTS® - VIVUS starts Phase 3 trials Contraceptive sprays - start proof of concept trials of combinations Testosterone MD-Lotion® - complete Phase 2 trials New p
Slide 14: Licensing - further deal opportunities
i i a Licensing - further deal opportunities Evamist™ - FDA approval of EvaMist™ marketing application and US$3m milestone from VIVUS (Q4 2007) Testosterone MDTS® - confirm US Phase 3 requirements (mid-2007); progress Europe commercialisation options (H2 2007) Testosterone MD-Lotion® - Phase 2 trial